- Reuters•19 hours ago
Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson . More than 66 percent of Cosentyx patients achieved "clear or almost clear" skin after four years, Novartis said, comparable with the 68.5 percent who hit that milestone after one year. A durable response is important, since older biotech drugs for plaque psoriasis, known as anti-TNFs, can lose their effectiveness over time.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) top line results from a mid-stage study of Eylea co-formulated with rinuccumab didn't meet its primary endpoint. Chardan's Sell rating was predicated on risks ...
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
|Bid||165.55 x 100|
|Ask||168.68 x 400|
|Day's Range||165.26 - 167.72|
|52wk Range||138.06 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.07|
|Avg Vol (3m)||2,849,579|
|Dividend & Yield||4.00 (2.42%)|